⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TGTX News
TG Therapeutics, Inc.
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
globenewswire.com
TGTX
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
globenewswire.com
TGTX
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
TGTX
Form 8-K
sec.gov
TGTX
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
globenewswire.com
TGTX
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
globenewswire.com
TGTX
Ublituximab Market Research Report 2026: $2.24 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
TGTX
Form 8-K
sec.gov
TGTX
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
globenewswire.com
TGTX
Global Stem Cell Therapy Market Set to Flourish at a CAGR of ~11% by 2034 Owing to the Technological Advancements and Favorable Regulations | DelveInsight
globenewswire.com
ADAG
ABBV
BIIB
BMRN
BLRX
CNSP
CYCN
GEN
GILD
GRAF
GSK
HSIC
HUBS
IBIO
INCY
JAZZ
JNJ
MAGN
MARA
MRK
NVS
OMER
PFE
PRGS
REGN
RGNX
SRPT
TENB
TGLS
TGTX
TNDM
TXG
VRTX